EMPACT-MI trial; empagliflozin; SGTL2i; MI; heart failure

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
ACC.24
Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
- James Januzzi, MD
Angiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
Angiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
ACC.24
Angiotensinogen RNAi therapeutic lowers blood pressure in combination with standard antihypertensive
- Akshay S. Desai, MD
Preventive PCI versus optimal medical therapy only for vulnerable plaques
Preventive PCI versus optimal medical therapy only for vulnerable plaques
ACC.24
Preventive PCI versus optimal medical therapy only for vulnerable plaques
- Marc Bonaca, MD
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
ACC.24
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
- Alexander J. Blood, MD

No effect on the primary endpoint with SGLT2i post-MI, but significant effect on HF hospitalizations